As a first-in-class precision medicine based company we prioritize disorders such as Dravet syndrome where there are no currently approved drugs to effectively treat these patients.
Finding new uses for existing drugs allows us to significantly mitigate development risks including safety and early non-clinical development costs. We can save enormous development time to the market through bypassing early development processes. Together with zebrafish disease models mimicking rare genetic disorders, this approach allows us to bring the right solution to the right patient in a precise, cost-efficient, and prompt manner.